Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.
Status:
Unknown status
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
A prospective, open, multicenter,demonstrative of PrEP, which aims to assess the
acceptability, feasibility and safety from chemoprophylaxis co-formulated emtricitabine /
tenofovir disoproxil fumarate (FTC / TDF) administered orally, once daily, to MSM and
transgender women . The demonstration project aims to include 400 participants over 12
months, with 200 at IPEC-Fiocruz, 100 at CRT-SP and 100 at USP.
Phase:
N/A
Details
Lead Sponsor:
Oswaldo Cruz Foundation
Collaborators:
Centro de Referência e Treinamento DST AIDS University of Sao Paulo
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir